Tuesday, April 13th, 2010.

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer Research’s (AACR) 101st Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. from April 17-21, 2010.

The posters will include data on Rosetta Genomics’ unique microRNA-based technologies and how they may be applied to develop objective and standardized diagnostic tests for cancer.

“This cumulative body of clinical data underscores the important role microRNAs can play in diagnosing and treating a variety of cancers,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. “We continue to build upon our scientific and clinical data to further validate the strength of our microRNA platform technologies, and demonstrate our ability to harness the power of microRNAs to advance the standard of care in diagnosing and treating cancer.”

Presented posters:

• “One microRNA Has Prognostic Potential For Malignant Pleural Mesothelioma” Tuesday, April 20 from 2:00 PM – 5:00 PM, Exhibit Hall A-C, Poster Section 7, Abstract #4053
• “Prognostic value of microRNAs expression in diffuse large B cell lymphoma” Tuesday, April 20 from 2:00 PM – 5:00 PM, Exhibit Hall A-C, Poster Section 7, Abstract #4054
• “microRNAs as prognostic indicators in gastric cancer” Tuesday, April 20 from 9:00 AM – 12:00 PM, Exhibit Hall A-C, Poster Section 3, Temporary Abstract #5296
• “microRNAs as a powerful diagnostic tool for the differential diagnosis of kidney tumors” Tuesday, April 20 from 9:00 AM – 12:00 PM, Exhibit Hall A-C, Poster Section 3, Abstract #3019

About microRNAs

MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. MicroRNAs’ unique advantage as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19-21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit www.rosettagenomics.com.

About miRview(TM) Products

miRview(TM) are a series of microRNA-based diagnostic tests developed by Rosetta Genomics. miRview(TM) mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary (CUP) patients. miRview(TM) squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain targeted therapies. miRview(TM) meso diagnoses mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura. This test can be used to rule out mesothelioma in patients diagnosed with a tumor in the lung or pleura, who may have been exposed to asbestos in the past. miRview(TM) tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. The company’s tests are now being offered through distributors around the globe. For more information, please visit www.mirviewdx.com.

About Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview(TM) squamous, miRview(TM) mets and miRview(TM) meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com.

« Mesothelioma News Main Page.

Posted: Tuesday, April 13th, 2010 at 11:28 am; filed under Asbestos & Mesothelioma Studies, Drug Companies, Novel Treatments & Drugs, Rosetta Genomics.

You can follow any responses to this entry through the RSS 2.0 feed.

You can skip to the end and leave a response. Pinging is currently not allowed.